Microneedling for hair loss is an increasingly popular minimally invasive scalp treatment that uses fine needles to stimulate the body's natural healing response and potentially encourage hair regrowth. By creating controlled micro-injuries in the scalp, the procedure aims to activate dormant hair follicles and enhance the absorption of topical treatments such as minoxidil. While clinical research — particularly for androgenetic alopecia — shows promising results, microneedling is not yet a first-line treatment under UK guidelines. This article explains how it works, what the evidence shows, who may be suitable, and how to access safe, regulated treatment in the UK.

What Is Microneedling and How Does It Work for Hair Loss?

Microneedling uses a fine-needle device to create micro-injuries in the scalp, stimulating growth factors and potentially activating dormant hair follicles; it may also enhance absorption of topical treatments such as minoxidil, though the underlying mechanisms remain largely theoretical in humans.

Microneedling, also known as collagen induction therapy or percutaneous collagen induction, is a minimally invasive procedure that uses a device studded with fine, sterile needles to create controlled micro-injuries in the skin. When applied to the scalp, these tiny punctures are thought to stimulate the body's natural wound-healing response, triggering the release of growth factors and promoting cellular regeneration in the hair follicle environment.

The proposed mechanisms of action for hair loss centre on several biological pathways. The micro-injuries are thought to stimulate the release of platelet-derived growth factor (PDGF), vascular endothelial growth factor (VEGF), and Wnt/β-catenin signalling, all of which may play a role in activating dormant hair follicle stem cells and prolonging the anagen (growth) phase of the hair cycle. It is important to note that these mechanisms, whilst biologically plausible, remain largely theoretical in humans and have not been definitively confirmed in large-scale clinical trials. Additionally, microneedling is thought to enhance the absorption of topical treatments — such as minoxidil — by temporarily increasing scalp permeability, though this effect also carries implications for increased systemic absorption and potential adverse effects (see the section on risks below).

Experiencing these side effects? Our pharmacists can help you navigate them →

Devices used for scalp microneedling include:

• Dermarollers — handheld rollers with needle lengths typically between 0.5 mm and 1.5 mm

• Dermapens or automated microneedling pens — motorised devices offering more precise depth control

• Radiofrequency microneedling devices — combining needling with thermal energy, used in clinical settings; evidence for their use specifically in hair loss is currently very limited and they should be considered experimental in this context

It is important to distinguish between professional-grade treatments performed in regulated clinical environments and at-home devices, which carry different risk profiles and efficacy levels. At-home devices should not be shared between individuals due to infection risk. For hair loss, needle depths of 0.5 mm to 1.0 mm are commonly referenced in the literature, though optimal depth and frequency have not been established and protocols vary considerably across studies and clinical settings. Patients should not interpret any specific depth as a recommended standard.

Evidence and Clinical Research Behind Microneedling for Hair Loss

Clinical evidence, including a key 2013 RCT, suggests microneedling combined with minoxidil improves hair count in androgenetic alopecia more than minoxidil alone, but overall evidence quality is moderate and it is not endorsed as a first-line treatment by NICE or the BAD.

The evidence base for microneedling as a treatment for hair loss has grown over the past decade, though it remains an emerging field and is not considered a first-line treatment by major UK clinical guidelines, including those from NICE or the British Association of Dermatologists (BAD). The majority of research has focused on androgenetic alopecia (AGA) — the most common form of hair loss in both men and women — with some studies also examining its use in alopecia areata.

Not sure if this is normal? Chat with one of our pharmacists →

A frequently cited randomised controlled trial published in the Journal of Cutaneous and Aesthetic Surgery (Dhurat et al., 2013) compared microneedling combined with minoxidil against minoxidil alone in men with AGA. The microneedling group demonstrated significantly greater hair count improvement at 12 weeks, suggesting a potential synergistic effect. More recent systematic reviews and meta-analyses have broadly supported these findings, concluding that microneedling — particularly when combined with topical minoxidil or platelet-rich plasma (PRP) — may offer clinically meaningful improvements in hair density and thickness in AGA. However, the overall quality of evidence remains moderate at best.

It is important to note several limitations in the current evidence:

• Many studies are small in scale and lack long-term follow-up data; durability of benefit is not established

• There is significant heterogeneity in treatment protocols (needle depth, frequency, device type), making direct comparisons difficult

• Most trials have been conducted outside the UK, limiting direct applicability to UK populations and clinical settings

• Placebo-controlled blinding is methodologically challenging in needling studies

• Evidence for conditions other than AGA — including alopecia areata, telogen effluvium, and traction alopecia — is considerably more limited

In UK clinical practice, established first-line treatments for androgenetic alopecia include topical minoxidil (available over the counter) and oral finasteride (for suitable men, on prescription). Microneedling should be considered a potential adjunct to these licensed treatments, not a replacement. Patients are encouraged to discuss first-line options with their GP or a dermatologist before pursuing microneedling. Neither NICE nor the MHRA has issued specific guidance endorsing microneedling as a standalone treatment for hair loss.

Who May Be Suitable for Microneedling Treatment in the UK?

Microneedling is best evidenced for androgenetic alopecia in adults following a thorough clinical assessment; it is contraindicated in those with active scalp infections, scarring alopecia, bleeding disorders, or anticoagulant use, and red-flag symptoms require urgent GP or dermatology referral first.

Microneedling for hair loss is not universally appropriate, and a thorough clinical assessment is essential before commencing treatment. In the UK, reputable practitioners will conduct a detailed consultation to determine suitability, which may include reviewing medical history, examining the scalp, and in some cases arranging blood tests to exclude underlying causes of hair loss.

Common baseline investigations in UK primary care include full blood count (FBC), serum ferritin, and thyroid function tests (TFTs). In women with clinical features suggesting hyperandrogenism (e.g., irregular periods, acne, hirsutism), serum androgens may also be checked. These investigations are typically guided by the clinical picture and are best arranged via a GP.

Conditions where microneedling may be considered include:

• Androgenetic alopecia (male and female pattern hair loss) — the best-evidenced indication

• Alopecia areata (patchy hair loss) — evidence is more limited; specialist input is advisable

• Traction alopecia in early stages — evidence is sparse; addressing the underlying hair-care practices should be the primary intervention

• Hair thinning associated with telogen effluvium — evidence is limited; the underlying trigger should be identified and addressed first, and microneedling should not be pursued until the condition has stabilised

Microneedling is generally not recommended for individuals who:

• Have active scalp infections (including suspected tinea capitis, which requires urgent dermatological assessment and antifungal treatment before any needling procedure)

• Have active psoriasis, eczema, or seborrhoeic dermatitis in the treatment area

• Are taking anticoagulant medications (e.g., warfarin, apixaban, rivaroxaban) or antiplatelet agents (e.g., aspirin, clopidogrel) due to increased bleeding risk — patients must not stop these medicines without first consulting their prescriber

• Have a bleeding disorder (e.g., haemophilia, von Willebrand disease)

• Have a history of keloid scarring or poor wound healing

• Are pregnant or breastfeeding

• Have active or recent scalp malignancy

Red flags requiring urgent GP or dermatology referral before any aesthetic intervention: Patients presenting with scalp pain or burning, perifollicular erythema or scaling, rapidly progressive hair loss, visible scarring of the scalp, pustules, or associated nail or mucosal changes may have a scarring (cicatricial) alopecia — such as lichen planopilaris or frontal fibrosing alopecia — or another condition requiring specialist diagnosis and treatment. Microneedling is not appropriate in these circumstances and could cause harm. Suspected tinea capitis (scalp ringworm) also requires urgent assessment and treatment.

Age is also a consideration; microneedling is typically offered to adults, and its use in younger patients or children should only be undertaken within specialist care. Individuals with significant psychological distress related to hair loss should be offered appropriate psychological support alongside any physical treatment. A GP referral to a dermatologist may be warranted to confirm the diagnosis and rule out treatable underlying causes before pursuing any aesthetic intervention.

What to Expect During and After a Microneedling Session

A scalp microneedling session typically lasts 20–45 minutes, with mild redness and tenderness resolving within 24–48 hours; a course of 4–6 sessions spaced two to four weeks apart is standard, with visible hair improvements taking three to six months.

A typical scalp microneedling session in a UK clinic begins with a thorough cleansing of the scalp to reduce infection risk. A topical anaesthetic cream is often applied 30 to 45 minutes beforehand to minimise discomfort, particularly when using longer needle depths. Patients with a known allergy to local anaesthetics should inform their practitioner before any anaesthetic cream is applied. The practitioner will then systematically pass the microneedling device across the affected areas of the scalp, applying consistent pressure to ensure uniform penetration depth.

The procedure itself usually lasts between 20 and 45 minutes, depending on the size of the treatment area. Patients typically describe the sensation as a mild scratching or tingling; discomfort is generally well tolerated with adequate anaesthesia.

A note on post-needling application of topical agents: Some practitioners apply topical agents — such as minoxidil solution or platelet-rich plasma (PRP) — immediately after needling to take advantage of the enhanced skin permeability. Patients should be aware that applying minoxidil to freshly needled scalp skin is off-label and is not supported by the UK Summary of Product Characteristics (SmPC) for topical minoxidil products (e.g., Regaine), which advises against application to irritated or damaged skin due to the risk of increased irritation and enhanced systemic absorption. Many UK clinicians therefore advise withholding topical minoxidil for 24 to 48 hours following a microneedling procedure. Patients should discuss this with their practitioner and, if using prescribed or over-the-counter minoxidil, with their GP or pharmacist.

Immediately after treatment, patients can expect:

• Redness and mild swelling of the scalp, usually resolving within 24–48 hours

• Mild tenderness or sensitivity to touch

• Occasional pinpoint bleeding, which settles quickly

Post-treatment care advice typically includes:

• Avoiding washing the hair for 24 hours

• Refraining from vigorous exercise or excessive sweating for 24–48 hours

• Avoiding swimming pools, saunas, steam rooms, and hot tubs for 48–72 hours to reduce infection risk

• Avoiding direct sun exposure and using SPF protection on exposed areas

• Not applying harsh chemical products (e.g., hair dyes, strong styling products) for at least 72 hours

• Avoiding tight headwear or heat styling for 24–48 hours

Most treatment protocols recommend a course of 4 to 6 sessions, spaced two to four weeks apart, before assessing response. Visible improvements in hair density may take three to six months to become apparent, as the hair growth cycle is slow. Patients should be counselled to have realistic expectations and understand that maintenance sessions may be required.

Risks, Side Effects, and Safety Considerations

Common risks include transient redness and scalp tenderness; more serious risks include infection, blood-borne virus transmission from shared needles, post-inflammatory hyperpigmentation, and scarring, all of which are minimised by using a qualified practitioner with sterile single-use equipment.

Microneedling is generally considered a safe procedure when performed by a trained and competent practitioner using sterile, single-use equipment. However, as with any skin-penetrating intervention, there are recognised risks and side effects that patients should be fully informed about prior to consenting to treatment.

Common side effects include:

• Transient erythema (redness) and oedema (swelling)

• Scalp tenderness and sensitivity

• Mild bruising in some individuals

Less common but more serious risks include:

• Infection — bacterial (including folliculitis and impetigo) or viral (including herpes simplex reactivation), particularly if equipment is not properly sterilised or aftercare instructions are not followed. There is also a risk of blood-borne virus (BBV) transmission (e.g., hepatitis B, hepatitis C, HIV) if needles or devices are shared or reused — patients should confirm that sterile, single-use needle cartridges are used for every treatment

• Post-inflammatory hyperpigmentation — more common in individuals with darker skin tones (Fitzpatrick skin types IV–VI)

• Scarring — rare but possible, particularly with excessive needle depth or frequency

• Allergic or irritant reactions — to topical agents applied during or after the procedure, including minoxidil, antiseptic solutions, and anaesthetic creams; contact dermatitis can occur

Patients should ensure that any device used carries a UKCA or CE mark, confirming it meets applicable safety standards. Practitioners should be able to demonstrate robust infection-control protocols, use of sterile single-use needle cartridges, and clear pathways for managing complications.

Regulatory context in the UK: Aesthetic practice in the UK is regulated across several frameworks. Professional regulators — including the General Medical Council (GMC), Nursing and Midwifery Council (NMC), General Pharmaceutical Council (GPhC), and Health and Care Professions Council (HCPC) — set standards for registered healthcare professionals. The Care Quality Commission (CQC) registers and inspects providers of specified regulated activities in England; not all aesthetic clinics fall within CQC scope, so patients should check whether a given clinic is required to be registered. The Department of Health and Social Care (DHSC) has announced plans to introduce a licensing scheme for non-surgical cosmetic procedures under the Health and Care Act 2022; as of the time of writing, this scheme is not yet fully in force, and patients should check the current status of these regulations.

Reporting adverse incidents: If you experience an unexpected adverse reaction to a treatment or suspect a problem with a medical device used during your procedure, you can report this to the MHRA via the Yellow Card Scheme (yellowcard.mhra.gov.uk). This helps the MHRA monitor the safety of medicines and medical devices in the UK.

Patients should contact their GP or seek urgent advice if they experience:

• Signs of infection (spreading redness, warmth, swelling, pus, or fever)

• Severe or worsening pain

• Unexpected or excessive hair shedding beyond the normal post-treatment period

• Any unusual skin changes, scarring, or pigmentation changes in the treated area

Accessing Microneedling for Hair Loss Through UK Clinics and the NHS

Microneedling for hair loss is predominantly available privately in the UK, costing £100–£400 per session, as it is not routinely commissioned by the NHS; patients should verify practitioner registration with the GMC, NMC, or GPhC and consult their GP first to exclude underlying causes.

In the United Kingdom, microneedling for hair loss is predominantly available through private aesthetic clinics and dermatology practices. It is not routinely commissioned by the NHS for cosmetic hair loss, as hair restoration treatments are generally classified as low clinical priority procedures by local Integrated Care Boards (ICBs). Patients should be aware that NHS access to microneedling for hair loss is uncommon and subject to local ICB policies. However, NHS dermatology departments may occasionally consider microneedling as part of a broader treatment plan for specific conditions such as alopecia areata, particularly in cases that have not responded to conventional therapies.

For those seeking private treatment, costs in the UK typically range from £100 to £400 per session, depending on the clinic, location, and whether adjunct treatments such as PRP are included. Given that multiple sessions are usually required, patients should budget accordingly and be cautious of clinics offering unrealistically low prices, which may reflect compromised standards of care or equipment.

When selecting a provider, patients are advised to:

• Verify the practitioner's qualifications — look for registered healthcare professionals such as doctors (GMC-registered), nurses (NMC-registered), or pharmacists (GPhC-registered) with relevant aesthetic training and appropriate indemnity insurance

• Check for CQC registration where the clinic provides regulated activities in England

• Ask about voluntary accreditation — organisations such as the Joint Council for Cosmetic Practitioners (JCCP) and accredited registers such as Save Face provide additional quality markers for aesthetic practitioners

• Confirm device quality — ensure UKCA or CE-marked devices and sterile single-use needle cartridges are used as standard practice

• Ask about complication management — a reputable clinic should have clear protocols for managing adverse events and escalating to medical care if needed

• Request a formal consultation before committing to a course of treatment

For individuals concerned about hair loss, the most appropriate first step is to consult their GP, who can assess for underlying medical causes, arrange relevant investigations, initiate first-line treatments such as topical minoxidil or finasteride (where appropriate), and refer to an NHS or private dermatologist if needed. The NHS Hair Loss page (nhs.uk) provides a useful starting point for understanding common causes and when to seek help. Organisations such as the British Association of Dermatologists (BAD) and Alopecia UK also provide reliable patient information and can help individuals navigate their treatment options with confidence.

Frequently Asked Questions